Cancer statistics, 2018
TLDR
The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak.Abstract:
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the National Center for Health Statistics. In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2005-2014) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006-2015) declined by about 1.5% annually in both men and women. The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak. Of the 10 leading causes of death, only cancer declined from 2014 to 2015. In 2015, the cancer death rate was 14% higher in non-Hispanic blacks (NHBs) than non-Hispanic whites (NHWs) overall (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13-1.15), but the racial disparity was much larger for individuals aged <65 years (DRR, 1.31; 95% CI, 1.29-1.32) compared with those aged ≥65 years (DRR, 1.07; 95% CI, 1.06-1.09) and varied substantially by state. For example, the cancer death rate was lower in NHBs than NHWs in Massachusetts for all ages and in New York for individuals aged ≥65 years, whereas for those aged <65 years, it was 3 times higher in NHBs in the District of Columbia (DRR, 2.89; 95% CI, 2.16-3.91) and about 50% higher in Wisconsin (DRR, 1.78; 95% CI, 1.56-2.02), Kansas (DRR, 1.51; 95% CI, 1.25-1.81), Louisiana (DRR, 1.49; 95% CI, 1.38-1.60), Illinois (DRR, 1.48; 95% CI, 1.39-1.57), and California (DRR, 1.45; 95% CI, 1.38-1.54). Larger racial inequalities in young and middle-aged adults probably partly reflect less access to high-quality health care. CA Cancer J Clin 2018;68:7-30. © 2018 American Cancer Society.read more
Citations
More filters
Journal ArticleDOI
Ovarian cancer statistics, 2018.
Lindsey A. Torre,Britton Trabert,Carol DeSantis,Kimberly D. Miller,Goli Samimi,Carolyn D. Runowicz,Mia M. Gaudet,Ahmedin Jemal,Rebecca L. Siegel +8 more
TL;DR: Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection.
Journal ArticleDOI
Breast cancer statistics, 2019.
Carol DeSantis,Jiemin Ma,Mia M. Gaudet,Lisa A. Newman,Kimberly D. Miller,Ann Goding Sauer,Ahmedin Jemal,Rebecca L. Siegel +7 more
TL;DR: Breast cancer was the leading cause of cancer death in women in four Southern and two Midwestern states among blacks and in Utah among whites during 2016‐2017, and could be accelerated by expanding access to high‐quality prevention, early detection, and treatment services to all women.
Journal ArticleDOI
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Thierry Conroy,Pascal Hammel,Mohamed Hebbar,Meher Ben Abdelghani,Alice C. Wei,Jean-Luc Raoul,Laurence Chone,Eric Francois,Pascal Artru,James Joseph Biagi,Thierry Lecomte,Eric Assenat,Roger Faroux,Marc Ychou,Julien Volet,Alain Sauvanet,Gilles Breysacher,Frédéric Di Fiore,Christine Cripps,Petr Kavan,Patrick Texereau,Karine Bouhier-Leporrier,Faiza Khemissa-Akouz,Jean-Louis Legoux,Beata Juzyna,Sophie Gourgou,Christopher J. O'Callaghan,Claire Jouffroy-Zeller,Patrick Rat,David Malka,Florence Castan,Jean-Baptiste Bachet +31 more
TL;DR: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects.
Journal ArticleDOI
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.
TL;DR: Up-to-date statistics on pancreatic cancer occurrence and outcome along with a better understanding of the etiology and identifying the causative risk factors are essential for the primary prevention of this disease.
Journal ArticleDOI
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Thorsten Oliver Goetze,Johannes Meiler,Stefan Kasper,Hans-Georg Kopp,Frank Mayer,Georg Martin Haag,Kim Barbara Luley,U. Lindig,Wolff Schmiegel,Michael Pohl,Jan Stoehlmacher,Gunnar Folprecht,Stephan Probst,Nicole Prasnikar,Wolfgang Fischbach,Rolf Mahlberg,Jörg Trojan,Michael Koenigsmann,Uwe M. Martens,Peter C. Thuss-Patience,Matthias Egger,Andreas Block,Volker Heinemann,Gerald Illerhaus,Markus Moehler,Michael Schenk,Frank Kullmann,Dirk M Behringer,Michael Heike,Daniel Pink,Christian Teschendorf,Carmen Löhr,Helga Bernhard,G. Schuch,Volker Rethwisch,Ludwig Fischer von Weikersthal,Jörg T. Hartmann,Michael Kneba,Severin Daum,Karsten Schulmann,Jörg Weniger,Sebastian Belle,Timo Gaiser,Fuat Oduncu,Martina Güntner,Wael Hozaeel,Alexander Reichart,Elke Jäger,Thomas Kraus,Stefan Mönig,Wolf O. Bechstein,Martin Schuler,Harald Schmalenberg,Ralf Hofheinz,Flot Aio Investigators +57 more
TL;DR: In this article, the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin, and doceteaxel) as a perioperative therapy for patients with locally advanced, resectable tumours was reported.
References
More filters
Journal ArticleDOI
Cancer statistics, 2012
TL;DR: The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of about 1,024,400 deaths from cancer, which can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket.
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.
SEER Cancer Statistics Review, 1975-2003
Lynn A. G. Ries,D. Harkins,Martin Krapcho,Angela B. Mariotto,Barry A. Miller,Eric J. Feuer,Limin X. Clegg,M. P. Eisner,Marie-Josèphe Horner,Nadia Howlader,Matthew J. Hayat,Benjamin F. Hankey,Brenda K. Edwards +12 more
Journal ArticleDOI
International Classification of Diseases for Oncology
TL;DR: Use ofImmunofluorescence in the Diagnosis of Virus Infections using audio-tape slide programme and slides and cassette by P. S. Gardner.
Journal ArticleDOI
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
TL;DR: The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation), which applies to men in the general U.S. population, regardless of age.